The Russian Direct Investment Fund (RDIF) and the pharmaceutical company Viscoran Ilac have signed an agreement for the production of the Sputnik V vaccine in Turkey. “We’ll increase the capacity with manufacturing in the country,” said Kirill Dmitriev, CEO of RDIF. Viscoran Ilac has already prepared its infrastructure to produce the vaccine at its facilities, according to a company statement. “Collaboration with the RDIF covers many fields, from licensing to clinical studies,” said Ozturk Oran, Founder of Viscoran Ilac. Manufacturing of the vaccine will start at several production plants in the upcoming months, both for local use and to third countries. The technology transfer for production is being finalized with CinnaGen while negotiations continue with two other producers in order to increase general production capacity.
Leave a Reply